Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience

BACKGROUND: Pertuzumab is a humanized anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody found in a Phase III clinical trial to significantly improve median survival in HER2 positive metastatic breast cancer (MBC) when used in combination with a taxane and Trastuzumab, and its...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahardja, Sylwan, Tan, Ryan Ying Cong, Sultana, Rehena, Leong, Fun Loon, Lim, Elaine Hsuen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103528/
https://www.ncbi.nlm.nih.gov/pubmed/32257845
http://dx.doi.org/10.5306/wjco.v11.i3.143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103528/
https://www.ncbi.nlm.nih.gov/pubmed/32257845
http://dx.doi.org/10.5306/wjco.v11.i3.143

Ejemplares similares